Thesan Pharmaceuticals Gets a $16M Dose of Series A Funds
November 01, 2012
Thesan Pharmaceuticals, a company focused on the development and commercialization of treatments for dermatological issues, has closed on $16 million in Series A financing. The round was co-led by Novo Ventures and Novartis Venture Funds. Financing will go toward continued development of novel topical treatments for a variety of dermatological diseases and conditions.